AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Seloken / Toprol-XL (metoprolol) — US YoY by Quarter
Seloken / Toprol-XL (metoprolol) — US YoY (%) (%)
AstraZeneca Seloken / Toprol-XL (metoprolol) — US YoY: 0.0% in Q2 2026. That is the highest of the 14 quarters on record here.
Latest, Q2 2026
0.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
14 quarters
Since Q4 2020
Sources
14
Documents cited below
Where the Q2 2026 figure comes from
“|| Seloken | 157 | | 6 | | 2 | | - | | - | | 153 | | 6 | | 2 | | 3 | | ( 1 ) | | ( 3 ) | | 1 | | 12 | | 4”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Seloken / Toprol-XL (metoprolol) — US YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0.0% | – | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 0.0% | – | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 0.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -96.0% | -96.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 0.0% | 0.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 0.0% | – | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 0.0% | 0.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | 0.0% | – | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | 0.0% | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | 0.0% | +83.0 pts | Form 6-K FY2022Q2 Earnings Release ↗ |
| Q3 2021 | Sep 30, 2021 | -81.0% | – | Form 6-K FY2021Q3 Earnings Release ↗ |
| Q2 2021 | Jun 30, 2021 | -83.0% | – | Form 6-K FY2021Q2 Earnings Release ↗ |
| Q1 2021 | Mar 31, 2021 | -90.0% | – | Form 6-K FY2021Q1 Earnings Release ↗ |
| Q4 2020 | Dec 31, 2020 | -52.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Seloken / Toprol-XL (metoprolol) — US YoY (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-seloken-us-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.